» Articles » PMID: 22690926

Risk Factors for a Non-favorable Outcome After Treated European Neuroborreliosis

Overview
Specialty Neurology
Date 2012 Jun 14
PMID 22690926
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To identify possible risk factors for reduced health-related quality of life (HRQoL) and fatigue after treated Lyme neuroborreliosis (LNB).

Methods: We included 50 patients with LNB and analyzed associations between their demographic, clinical, and laboratory characteristics at baseline and outcome at 30 months assessed by the self-report questionnaires Short Form-36 (SF-36) and Fatigue Severity Scale (FSS).

Results: Lower scores in the SF-36 domain Physical Component Summary were associated with pretreatment symptom duration >6 weeks (B = -11.0, P = 0.001) and non-complete recovery at 4 months (B = -5.5, P = 0.037) (R(2) = 0.35). Lower scores in the SF-36 domain Mental Component Summary were associated with non-complete recovery at 4 months (B = -8.9, P = 0.01 (R(2) = 0.14). Higher FSS scores were associated with pretreatment symptom duration >6 weeks (B = 1.4, P = 0.006), high scores on the composite clinical score pretreatment (B = 0.1, P = 0.003), and non-complete recovery at 4 months (B = 1.6, P = 0.005) (R(2) = 0.46). No laboratory test results were associated with these predefined outcomes.

Conclusions: Delayed treatment start, more symptoms and findings before treatment, and non-complete recovery at 4 months after treatment are possible predictors of a poorer HRQoL and more fatigue 30 months after treated LNB. We did not find age, gender, educational level, involvement of the central nervous system, coexisting diseases, or cerebrospinal fluid findings to be associated with reduced HRQoL or fatigue. Our findings should be replicated in future studies before any conclusions can be drawn.

Citing Articles

Current and emerging approaches for eliminating and alleviating persistent Lyme disease symptoms.

Zafar K, Azuama O, Parveen N Front Microbiol. 2024; 15:1459202.

PMID: 39345262 PMC: 11427371. DOI: 10.3389/fmicb.2024.1459202.


Clinical and laboratory characteristics during a 1-year follow-up in European Lyme neuroborreliosis: A prospective cohort study.

Solheim A, Skarstein I, Quarsten H, Lorentzen A, Berg-Hansen P, Eikeland R Eur J Neurol. 2024; 31(12):e16487.

PMID: 39297748 PMC: 11555137. DOI: 10.1111/ene.16487.


[Bilateral facial palsy: an atypical presentation of Lyme disease (a case report)].

Collignon S, Coenen F, Mols P, Chauvin C, Ngatchou W Pan Afr Med J. 2024; 47:156.

PMID: 38974695 PMC: 11226764. DOI: 10.11604/pamj.2024.47.156.43116.


Serum neurofilament light chain associates with symptom burden in Lyme neuroborreliosis patients: a longitudinal cohort study from Norway.

Skarstein I, Ulvestad E, Solheim A, Vedeler C, Ljostad U, Mygland A J Neurol. 2024; 271(5):2768-2775.

PMID: 38407594 PMC: 11055709. DOI: 10.1007/s00415-024-12237-z.


Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study.

Vrijmoeth H, Ursinus J, Harms M, Tulen A, Baarsma M, van de Schoor F EBioMedicine. 2023; 98:104825.

PMID: 38016860 PMC: 10755112. DOI: 10.1016/j.ebiom.2023.104825.